White House denies Trump is the well-connected man who gained compassionate access to obesity drug in April A White House spokesman said theories that President Trump sought the drug were baseless speculation Bookmark CommentsGo to comments Multiple White House officials are denying that President Donald Trump was the mystery patient who reportedly got early access to an experimental weight loss drug to treat severe health complications
Yet, they urge caution due to its complex pharmacokinetics and potential interactions with other drugs, especially hypoglycemics and antibiotics
Energy balance research
Hofflich said other patients who haven't seen progress on lower doses are starting to take higher doses to see if that will make a difference
Once stable on a dose, discuss moderate consumption with your provider
Key distinctions in the evidence: Tesamorelin: licensed in the US, narrowly indicated, established in HIV-related lipodystrophy, with effects that reverse on stopping treatment Retatrutide: investigational, broader metabolic potential, not yet approved anywhere globally Patients and clinicians should interpret early-phase data for retatrutide with appropriate caution
